Attendee search 

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract).

Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world’s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter's lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.

JRX Biotech is focused on (1) pain management and (2) dermatology applications.  We are a post revenue specialty biochemistry technology company.

We develop topical products using our patented delivery system platform (formfactors: liquid solutions, serums, lotions, creams, sprays).

DermX Megasphere Delivery System -- a dermal/transdermal delivery system technology platform that has been independently proven to allow high payloads of large molecular weight molecules to passively penetrate into and through human skin.

DermX Features / Benefits:

  --Passive, topical solution

  --Patented

  --Proven (Franz Cell and in vivo)

  --High payloads delivered (>20% of the applied dose penetrating)

  --Large molecules delivered (>11kD)

  --No irritation

We are looking to:

  (1) Co-develop our lead topical pain relief patented product (first-in-class).

  (2) Co-develop our pipeline of patented topical pain relief products.

  (3) Out-license our platform delivery system technology.